Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
 
 

Innovative Health Care, 20  Ticker: FNPUFX
 
Description
A unit investment trust that seeks above-average capital appreciation. The portfolio provides access to health care companies that are involved in the areas that we believe are driving innovation.
Please note that there is no assurance the objective will be met.
 
Summary
Product Code: INHC20
Portfolio Status: Primary
Initial Offer Date: 03/18/2024
Portfolio Ending Date: 06/18/2025
Tax Structure: Regulated Investment Company
Distributions: Semi-Annual
 
Initial Offer Price: $10.0000
NAV(*): $9.9929
POP(*): $10.1303
Remaining Deferred Sales Charge: $0.1350
* As of Trade Date: 05/20/2024 4:00pm ET
The Public Offering Price (POP) represents the net asset value per unit plus any applicable organization costs and sales charges. The Net Asset Value (NAV) represents the value per unit of a trust’s portfolio securities and other assets reduced by applicable deferred sales charges and other liabilities.

 Historical 12-Month Distribution of Trust Holdings:^
Rate (as of 5/20/2024) Per Unit (as of 5/17/2024)
0.43% $0.04390
^ There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The historical 12-month distribution per unit and historical 12-month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's distribution or distribution rate. The historical 12-month distribution per unit is based on the weighted average of the trailing twelve month distributions paid by the securities included in the portfolio. The historical 12-month distribution rate is calculated by dividing the historical 12-month distributions by the trust's offering price. The historical 12-month distribution and rate are reduced to account for the effects of fees and expenses, which will be incurred when investing in a trust. Certain of the issuers may have reduced their dividends or distributions over the prior twelve months. The distribution per unit and rate paid by the trust may be higher or lower than the amount shown above due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, or the sale of securities in the portfolio. For trusts that include funds, distributions may include realized short term capital gains, realized long-term capital gains and/or return of capital.

 Holdings Analysis Click here to Perform a Benchmark Comparison  
 Sector Weighting
Communication Services  Communication Services 0.00%
Consumer Discretionary  Consumer Discretionary 0.00%
Consumer Staples  Consumer Staples 0.00%
Energy  Energy 0.00%
Financials  Financials 0.00%
Health Care  Health Care 99.96%
Industrials  Industrials 0.00%
Information Technology  Information Technology 0.00%
Materials  Materials 0.00%
Real Estate  Real Estate 0.00%
Utilities  Utilities 0.00%
Other  Other 0.04%
 
  Large Mid Small  
Growth  37.66% 17.84% 5.43%  
Value  17.99% 18.04% 3.00%  

 Style Weighting
Large-Cap Growth 37.66%
Large-Cap Value 17.99%
Mid-Cap Growth 17.84%
Mid-Cap Value 18.04%
Small-Cap Growth 5.43%
Small-Cap Value 3.00%
Undetermined 0.04%
 Composition
U.S. Stocks 84.35%   Other 0.04%
Non-U.S. Stocks 15.61%      
The style and sector characteristics of the portfolio are determined as of 05/17/2024 and will likely vary thereafter due to market fluctuations in the underlying securities.  

 Key Stats
Weighted Average Market Cap $105,939
Price/Earnings 35.36
Price/Book 4.43
As of 5/17/2024
All market capitalization numbers are in USD$ Millions. All figures are subject to change.

 Holdings  Export Current Holdings | View Initial Holdings  
NameSymbolSectorStyleWeighting
 Koninklijke Philips N.V. (New York Registry Shares) PHG Health Care  Health Care Mid-Cap Value 3.39%
 Moderna, Inc. MRNA Health Care  Health Care Large-Cap Value 3.15%
 Ligand Pharmaceuticals Inc. (Class B) LGND Health Care  Health Care Small-Cap Value 3.00%
 Amgen Inc. AMGN Health Care  Health Care Large-Cap Growth 2.92%
 United Therapeutics Corporation UTHR Health Care  Health Care Mid-Cap Value 2.90%
 AstraZeneca Plc (ADR) AZN Health Care  Health Care Large-Cap Growth 2.88%
 Bio-Techne Corporation TECH Health Care  Health Care Mid-Cap Growth 2.87%
 Vertex Pharmaceuticals Incorporated VRTX Health Care  Health Care Large-Cap Growth 2.77%
 Merck & Co., Inc. MRK Health Care  Health Care Large-Cap Growth 2.70%
 Halozyme Therapeutics, Inc. HALO Health Care  Health Care Mid-Cap Growth 2.70%
 Sarepta Therapeutics, Inc. SRPT Health Care  Health Care Mid-Cap Growth 2.62%
 Thermo Fisher Scientific Inc. TMO Health Care  Health Care Large-Cap Value 2.59%
 Biogen Inc. BIIB Health Care  Health Care Large-Cap Value 2.59%
 Agilent Technologies, Inc. A Health Care  Health Care Large-Cap Growth 2.59%
 Medtronic Plc MDT Health Care  Health Care Large-Cap Value 2.52%
 Alnylam Pharmaceuticals, Inc. ALNY Health Care  Health Care Mid-Cap Growth 2.51%
 Zoetis Inc. ZTS Health Care  Health Care Large-Cap Growth 2.49%
 Intuitive Surgical, Inc. ISRG Health Care  Health Care Large-Cap Growth 2.48%
 Novo Nordisk A/S (ADR) NVO Health Care  Health Care Large-Cap Growth 2.47%
 DexCom, Inc. DXCM Health Care  Health Care Large-Cap Growth 2.46%
 Steris Plc STE Health Care  Health Care Mid-Cap Growth 2.46%
 Regeneron Pharmaceuticals, Inc. REGN Health Care  Health Care Large-Cap Value 2.45%
 Hologic, Inc. HOLX Health Care  Health Care Mid-Cap Growth 2.43%
 Incyte Corporation INCY Health Care  Health Care Mid-Cap Value 2.42%
 HealthEquity, Inc. HQY Health Care  Health Care Mid-Cap Value 2.42%
 Johnson & Johnson JNJ Health Care  Health Care Large-Cap Value 2.41%
 Eli Lilly and Company LLY Health Care  Health Care Large-Cap Growth 2.40%
 Zimmer Biomet Holdings, Inc. ZBH Health Care  Health Care Mid-Cap Value 2.40%
 Edwards Lifesciences Corporation EW Health Care  Health Care Large-Cap Growth 2.39%
 IQVIA Holdings Inc. IQV Health Care  Health Care Large-Cap Growth 2.31%
 Stryker Corporation SYK Health Care  Health Care Large-Cap Growth 2.29%
 Gilead Sciences, Inc. GILD Health Care  Health Care Large-Cap Value 2.28%
 AbbVie Inc. ABBV Health Care  Health Care Large-Cap Growth 2.28%
 BioMarin Pharmaceutical Inc. BMRN Health Care  Health Care Mid-Cap Value 2.27%
 Repligen Corporation RGEN Health Care  Health Care Mid-Cap Growth 2.25%
 Exelixis, Inc. EXEL Health Care  Health Care Mid-Cap Value 2.24%
 Veeva Systems Inc. (Class A) VEEV Health Care  Health Care Large-Cap Growth 2.23%
 CRISPR Therapeutics AG CRSP Health Care  Health Care Small-Cap Growth 1.89%
 Apellis Pharmaceuticals, Inc. APLS Health Care  Health Care Small-Cap Growth 1.80%
 Evolent Health, Inc. (Class A) EVH Health Care  Health Care Small-Cap Growth 1.74%
 
Total Number of Holdings:    40
Underlying Securities information represented above is as of 05/17/2024 but will vary with future fluctuations in the market.

 Standard Account Sales Charges *
Transactional sales charges: Initial:  0.03%
  Deferred:  1.33%
C&D Fee:    0.49%
Maximum Sales Charge:   1.85%
CUSIP Type Distribution
30335B181 Cash Semi-Annual
30335B199 Reinvest Semi-Annual
* Based on the offer price as of 05/20/2024 4:00pm ET

 Fee/Wrap Account Sales Charges *
C&D Fee:    0.50%
Maximum Sales Charge:   0.50%
CUSIP Type Distribution
30335B207 Cash-Fee Semi-Annual
30335B215 Reinvest-Fee Semi-Annual
* Based on the NAV price as of 05/20/2024 4:00pm ET
In addition to the sales charges listed, UITs for both brokerage and advisory accounts are subject to annual operating expenses and organization costs. See the prospectus for additional information.

 Deferred Sales Charge Schedule
Amount Date
$0.04500 June 20, 2024
$0.04500 July 19, 2024
$0.04500 August 20, 2024

Risk Considerations

Buy & Hold Risk – Taxable Trusts. This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

Closed-End Fund and ETF Risk. Closed-end funds and ETFs are subject to various risks, including management's ability to meet the fund's investment objective, and to manage the fund's portfolio when the underlying securities are redeemed or sold, during periods of market turmoil and as investors' perceptions regarding ETFs, closed-end funds or their underlying investments change. Unlike open-end funds, which trade at prices based on a current determination of the fund's net asset value, ETFs and closed-end funds frequently trade at a discount from their net asset value in the secondary market. Certain closed-end funds in which the portfolio invests may employ the use of leverage, which increases the volatility of such funds.

Closed-End Fund Risk. Closed-end funds are subject to various risks, including management's ability to meet the fund's investment objective, and to manage the fund's portfolio when the underlying securities are redeemed or sold, during periods of market turmoil and as investors' perceptions regarding the funds or their underlying investments change. Unlike open-end funds, which trade at prices based on a current determination of the fund's net asset value, closed-end funds frequently trade at a discount to their net asset value in the secondary market. Certain closed-end funds employ the use of leverage, which increases the volatility of such funds.

COVID-19 Economic Impact Risk. The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.

Health Care Risk. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry in particular.

Large-Cap Risk. Large capitalization companies may grow at a slower rate than the overall market.

Market Disruption Risk. Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain investments as well as performance.

Additional Risk. For a discussion of additional risks of investing in the trust see the "Risk Factors" section of the prospectus.

Important Note. It is important to note that an investment can be made in the underlying funds directly rather than through the trust. These direct investments can be made without paying the trust's sales charge, operating expenses and organizational costs.

Operational Risk. As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

The style and capitalization characteristics used to describe the stocks are designed to help you understand how they fit into your overall investment plan. Due to changes in the value of the stocks the characteristics may vary over time. In general, growth stocks have high relative price-to-book ratios while value stocks have low relative price-to-book ratios. In determining market capitalization characteristics, we analyze the market capitalizations of the 3,000 largest stocks in the U.S. (excluding foreign securities, ADRs, limited partnerships and regulated investment companies) on a monthly basis. Companies with market capitalizations among the largest 10% are considered Large-Cap securities, the next 20% are considered Mid-Cap securities and the remaining securities are considered Small-Cap securities.

You should carefully consider the trust's investment objectives, risks, and charges and expenses before investing. Contact your financial professional or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the trust. Read it carefully before you invest.

This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.

Not FDIC Insured, Not Bank Guaranteed and May Lose Value.

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.

Fund Cusip Information
30335B181 (Cash)
30335B199 (Reinvest)
30335B207 (Cash-Fee)
30335B215 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
Follow First Trust:  
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2024 All rights reserved.